Aspirin Use and All-Cause Mortality Among Patients Being Evaluated for Known or Suspected Coronary Artery Disease

Abstract

Aspirin has been shown to be associated with decreased cardiovascular morbidity in multiple clinical trials^1,2 but the association between aspirin use and all-cause mortality has been less well defined except in the setting of acute myocardial infarction.³ Although a few observational analyses have suggested a longer-term survival benefit,^4-6 it is not clear whether this benefit persists after accounting for treatment selection biases as well as established predictors of survival in patients with known or suspected coronary artery disease, in particular impaired exercise capacity, left ventricular dysfunction, and myocardial ischemia.